
				TICICAT	TE OE MANILINIO LINID	CD 27 CCD	61.0				BRINKS	
CERTIFICATE OF MAILING UNDER 37 CFR §1.8  I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with											HOFER	
sufficient postage, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the below date:												
	Date: November 1, 2007 Name: John Murray Signature:							_ [	GILSON			
						-			2		&LIONE	
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE												
In re Appln. of:			Dennis et al. /									
Appln. No.:			10/679,581 ( NOV 0.5 2007 y					Examiner: Edward J. Webmar				
Filed:			October 6, 2003					Art Unit: 1616				
For:			Novel Microemulsion and Micelle Systems for Solubilizing Drugs					Conf. No.: 3153				
Docket No:			11509/20									
TRANSMITTAL												
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450												
Sir:												
Attac	hed	l is/are:										
Supplemental Information Disclosure Statement; form PTO 1449 with 5 references												
$\boxtimes$	⊠ Return Receipt Postcard.											
Fee Calculation:												
No additional fee is required.												
	Small Entity.											
	An extension fee in an amount of \$ for amonth extension of time under 37 CFR § 1.136(a).											
	A۱	oetition or	processii	ng fee ir	n an amount of \$	under	37 CFR § 1	.17()	١.			
	Ar	additiona	I filing fee	e has be	en calculated as sh	own belov	w:					
					<del></del>		Sma	II Entity		Not a S	mall Entity	
	_	Claims Re After Ame	•		Highest No. Previously Paid For	Present Extra	Rate	Add'I Fee	OR	Rate	Add'l Fee	
Total				Minus	•		x \$25=			x \$50=		
Indep.				Minus			x 105=			x \$210=	<b></b>	
First P	rese	ntation of N	Multiple De	p. Claim			+\$185=		-	+ \$370=		
		_					Total	\$	<u></u>	Total	\$	
Fee P	•											
	Payment by credit card in the amount of \$ (Form PTO-2038 is attached).											
	Please charge Deposit Account No. 23-1925 in the amount of \$ for  A copy of this Transmittal is enclosed for this purpose.											
	and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925. A copy of this Transmittal is enclosed for this purpose.											
	Respectfully submitted,											

BRINKS HOFER GILSON &LIONE November 1, 2007 Date



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Dennis et al.

Appln. No.: 10/679,581 Examiner: Webman, Edward J.

Filed: October 6, 2003 Art Unit: 1616

For: Novel Microemulsion and Micelle

Systems for Solubilizing Drugs

Attorney Docket No: 11509/20

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and more particularly in accordance with 37 C.F.R. §1.97(b), Applicants hereby cite the following reference(s):

## Foreign Patent Documents

DOCUMENT NUMBER Number-Kind Code (if known)	DATE	COUNTRY
WO 92/40144A	Dec 1996	PCT
WO 99/32151A	Jul 1999	PCT
WO 94/08610A	Apr 1994	PCT
WO 00/78301A	Dec 2000	PCT

Applicants are enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 C.F.R. §1.98(a)(2). As each of the listed references is in English, no further commentary is believed to be necessary,

37 C.F.R §1.98(a)(3). Applicants respectfully request the Examiner's consideration of the above reference(s) and entry thereof into the record of this application.

By submitting this Statement, Applicants are attempting to fully comply with the duty of candor and good faith mandated by 37 C.F.R. §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 C.F.R. §1.56(a).

Applicants have calculated no fee to be due in connection with the filing of this Statement. However, the Director is authorized to charge any fee deficiency associated with the filing of this Statement to a deposit account, as authorized in the Transmittal accompanying this Statement.

Respectfully submitted,

November 1, 2007

Date

John Murray (Reg. No. 44251)